RaNA Therapeutics (Cambridge, MA) a development-stage biopharmaceutical company focused on platform that allows selective gene activation and therapeutic factor expression by targeting long, noncoding RNA, closed a $20.7M Series A financing. Participants include Monsanto, SR One and Atlas Venture.